Fremont, CA (PRWEB) July 01, 2014
Lutronic, a global leader of lasers and therapeutic devices for aesthetic and medical applications, announced today that the new Gold Handpiece for SPECTRA is now available in the United States, expanding the already robust workhorse to even more clinical applications. "The gold 585 nm handpiece now available on the Spectra Q-switched laser, has proven to significantly reduce the purplish-red color from acne lesions in studies conducted both at our clinic and international sites. We've found the color to be actually more distressing than the acne itself, to many of our patients." Stated Dr. Gilly Munivalli, Medical Director and Founder of Dermatology Laser and Vein Specialists, "It's great to finally have a no-downtime, painless treatment to resolve this issue that can occur during acne outbreaks and typically persists for many months after active acne has resolved. The gold handpiece has proven very beneficial for our patients and our practice."
The Gold handpiece and software upgrade provide users expanded settings and applications, allowing physicians to get superior reduction in redness that can remain after acne is resolved. The new settings and specialized handpiece produce the ideal combination of low fluence and peak power for the 585 nm wavelength to address redness. The Spectra Gold HP is the only device of its kind to deliver 5mm spot size, as well as a replaceable dye pack; these improvements ensure treatments are quick and economical.
"The Gold HP works by utilizing the high absorption of the 585 nm in deoxy- and oxy-hemoglobin at very short pulses and low fluence to photobiomodulate the microvasculature in an abnormal status without causing purpura." Stated Rich Cohen, Medical Director, "Over a series of 3-10 treatments using the Gold HP will reduce the redness associated with a range of conditions. Finally providing a physicians a solution to these difficult to treat conditions."
LUTRONIC's Dual-pulsed Q-switched Nd:YAG SPECTRA™ laser has been engineered to meet the growing demands of a busy clinic, and includes a variety of efficacious treatment options, customizable parameters, built-in safety and minimized downtimes, all at an affordable price.
With four distinct Q-switched mode wavelengths - 1064 nm, 532 nm, 585 nm, 650 nm, the robust Spectra has the versatility to provide your practice with a wide range of clinical options for treating your patients. Spectra offers the best in class tattoo removal with superior color coverage, and Lutronic continually expands its treatment applications; Spectra is the first Q-switched Nd:YAG laser cleared for the treatment of melasma. The technically advanced Spectra system offers an edge over other lasers and provides enhanced clinical outcomes.
To learn more about the Spectra, please visit: http://www.lutronic.com/SPECTRA.
Lutronic, a leading innovator in advanced aesthetic and medical laser and related technology, was established over 15 years ago to bring intuitive, robust, versatile devices that are affordable and efficacious to the worldwide medical community. Committed to improving medicine, Lutronic partners with key opinion leaders to advance science and ensure the efficacy of its systems. All systems are versatile and offer multiple setting and treatment options for customized treatments, which optimize outcomes for a wide variety of conditions and treatments including melasma, tattoo removal, soft tissue incision, vascular lesions, hair removal, wrinkle reduction, rejuvenation, body/facial contouring, chronic pain, healing and more.
With a focus on physician needs and patient outcomes, Lutronic dedicates time and funding toward the development of devices that offer features and improvements not found in today's market. Devoting more than 20% of revenues to R&D, Lutronic holds more than 130 current and pending patents worldwide. With more than 230 employees worldwide, Lutronic has offices in the US, Korea, China, Japan, and Europe, a worldwide network of distributors, focused R&D centers in both the US and Korea, and is ever-expanding.
Read the full story at http://www.prweb.com/releases/2014/07/prweb11988261.htm